Ann: Notice of Annual General Meeting/Proxy Form, page-19

First 19 Last

Share
Profile

Follow
DimDim

52 Posts.

11

17/04/24

23:40

Post #: 73396888
Share

Originally posted by signalFollower: ↑

The selling has been Patras Capital to curate their VWAP price and the 10% discount available to them under the Terms of the Convertible Notes.

They had 30 million shares soon after the 40 million was announced, which had consistently been dwindling down in accordance with that image in my first post (above) to the point where as of the 15th of April, Patras held just over 9m shares, and BNP Parabis <IB Aus Noms> had increased by 15 million shares over the same time, not all of the sold shares but a fair swag of them.

And then this morning as per the other announcement, they opted for another 15 million shares to be converted at the 1.8cents lockign in their 10% discount.

So there's a few possibilities the way I am thinking about it:

1). Patras are selling to themselves to gain the desired VWAP for the next qty of shares they want to opt in for and achieveing free carry on the parcel they're wishing to retain along the way.

or

2). it's a psuedo Cap Rasise in effect if the buyers on BNP Parabis <IB Aus Noms> - which stands for the Custodiall Holders on behalf of Interactive Brokers Australia (as far as I understand) have impeccible timing and went to the sidelines before the Convertible Note was announced and they're now chipping away there at the Buy side knowing that Patras will come to them to lock in the 10% discount and it's a discount on a lower VWAP if Patras does infact come to them too btw.

or

A combination of (1) and (2)

The absence of an escrow condition over the shares opted for by Patras is the shittest part of it all IMO (or one of the shittest parts I should say)

Just my opinions on the possibiilities that is, the only things I actually know is that Patras sold down to approx 9m shares (from 40m in early March) as of the 15th of April and BNP Parabis <IN AUS Noms> went up by 15 million shares in the same time.

Form your own opinions I guess, but they're mine.

Expand

This is selling via Bell Potter. Started in October 2023 soon after CR

AAU Price at posting: 2.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

There are more pages in this discussion • 4 more messages in this thread...

First 19 Last

Add AAU (ASX) to my watchlist

(20min delay)
Last 0.3¢		Change -0.001(25.0%)		Mkt cap ! $7.422M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.3¢	$3.235K	809.8K

Buyers (Bids)

No.	Vol.	Price($)
70	68763038	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	72085387	45

View Market Depth

No.	Vol.	Price($)
70	68763881	0.003
53	73774869	0.002
12	28499950	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	72085387	45
0.005	17607556	12
0.006	7500755	7
0.007	2472191	4
0.008	4875000	7

Last trade - 11.53am 04/10/2024 (20 minute delay)

AAU (ASX) Chart

Ann: Notice of Annual General Meeting/Proxy Form, page-19

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Notice of Annual General Meeting/Proxy Form, page-19

Top Stories

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News